Influence of the selective cholecystokinin antagonist L-364,718 on pain threshold and morphine analgesia.
The intracerebroventricular injection of the cholecystokinin-A receptor antagonist L-364,718, at the doses of 0.5, 5, 10 or 20 micrograms/mouse, while having no effect on pain threshold (hot plate, 51 degrees C), antagonized the analgesic activity of morphine (10 mg/kg i.p.). This effect was obtained with a dose of 10 micrograms/mouse and was associated with a reduction of brainstem opiate-binding sites.
Poggioli
R
R
Institute of Pharmacology, University of Modena, Italy.
Vergoni
A V
AV
Sandrini
M
M
Barbafiera
L
L
Marrama
D
D
Bertolini
A
A
D000698:Analgesia; D000818:Animals; D001570:Benzodiazepinones / Q000378:metabolism / Q000494:pharmacology*; D001933:Brain Stem / Q000378:metabolism; D002766:Cholecystokinin / Q000037:antagonists & inhibitors*; D020109:Devazepide; D005260:Female; D008297:Male; D051379:Mice; D009020:Morphine; D010146:Pain / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors; D012684:Sensory Thresholds
D001570:Benzodiazepinones; D011949:Receptors, Cholecystokinin; D009020:Morphine; D002766:Cholecystokinin; D020109:Devazepide